Literature DB >> 17898653

Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease.

Alenka J Brooks1, Evan J Begg, Mei Zhang, Chris M Frampton, Murray L Barclay.   

Abstract

Methotrexate (MTX) use in inflammatory bowel disease (IBD) is complicated by unpredictable efficacy and toxicity. In rheumatoid arthritis, total and individual red blood cell MTX polyglutamates (RBC MTXGlu1-5) correlate with disease activity and possibly toxicity, and therefore may be useful in guiding treatment. It is unclear if this applies in IBD. The aim of this pilot study was to measure total and individual RBC MTXGlu1-5 concentrations in patients with IBD to see if these relate to efficacy and adverse effects. RBC MTXGlu1--5 concentrations were measured on three occasions in 18 patients with IBD receiving MTX at a constant dose for 3 or more months. The intrapatient variability, expressed as the coefficient of variation, of RBC MTXGlu1-5 concentrations at steady state was determined, and disease activity and adverse effects were assessed against concentrations. The intrapatient coefficients of variation of individual MTXGlu1-5 varied from 12% to 27%. In Crohn's disease, higher RBC MTXGlu4&amp;5 concentrations correlated with worse disease activity (r = 0.42 and 0.53, respectively, P </= 0.03). RBC MTXGlu5 concentrations were higher in patients experiencing at least one adverse effect as a result of MTX compared with those without adverse effects (mean, 26.7 versus 11.1 nmol/8 x 10 RBCs; mean difference, 15.6; 95% confidence interval, 3.5-27.7; P = 0.04). Similar trends were observed for RBC MTXGlu4. Furthermore, patients who specifically experienced gastrointestinal adverse effects had higher RBC MTXGlu4&amp;5 concentrations than patients without (P = 0.03 and 0.04, respectively). In summary, RBC MTXGlu1-5 concentrations can be measured accurately with low intrapatient variation. Unexpectedly, RBC MTXGlu4&amp;5 concentrations correlated inversely with efficacy in Crohn's disease. RBC MTXGlu4&amp;5 concentrations were higher in patients experiencing adverse effects. These findings suggest that RBC MTXGlu1-5 concentration monitoring may be of value in IBD and could assist with planning of larger studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17898653     DOI: 10.1097/FTD.0b013e31811f39bb

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  14 in total

1.  Simplification of a pharmacokinetic model for red blood cell methotrexate disposition.

Authors:  Shan Pan; Julia Korell; Lisa K Stamp; Stephen B Duffull
Journal:  Eur J Clin Pharmacol       Date:  2015-09-26       Impact factor: 2.953

Review 2.  Optimizing conventional therapies for inflammatory bowel disease.

Authors:  Miles P Sparrow; Peter M Irving; Stephen B Hanauer
Journal:  Curr Gastroenterol Rep       Date:  2009-12

Review 3.  Understanding the time course of pharmacological effect: a PKPD approach.

Authors:  Daniel F B Wright; Helen R Winter; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

Review 4.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

5.  Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats.

Authors:  Dong-Yang Liu; Hoi-Kei Lon; Yan-Lin Wang; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Biopharm Drug Dispos       Date:  2013-04-07       Impact factor: 1.627

Review 6.  Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.

Authors:  Emilio G Quetglas; Zlatan Mujagic; Simone Wigge; Daniel Keszthelyi; Sebastian Wachten; Ad Masclee; Walter Reinisch
Journal:  World J Gastroenterol       Date:  2015-11-28       Impact factor: 5.742

7.  Potential Role of Methotrexate Polyglutamates in Therapeutic Drug Monitoring for Pediatric Inflammatory Bowel Disease.

Authors:  Ryan Morrow; Ryan Funk; Mara Becker; Ashley Sherman; Leon Van Haandel; Taina Hudson; Rebecca Casini; Valentina Shakhnovich
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-14

Review 8.  Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.

Authors:  Mehmet Coskun; Casper Steenholdt; Nanne K de Boer; Ole Haagen Nielsen
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 5.577

9.  A novel dried blood spot-LCMS method for the quantification of methotrexate polyglutamates as a potential marker for methotrexate use in children.

Authors:  Ahmed F Hawwa; Abdelqader Albawab; Madeleine Rooney; Lucy R Wedderburn; Michael W Beresford; James C McElnay
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

10.  Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis.

Authors:  Tatsuhiro Yamamoto; Kotaro Shikano; Toshihiro Nanki; Shinichi Kawai
Journal:  Sci Rep       Date:  2016-10-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.